MiNK Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2017-01-01
- Employees
- 31
- Market Cap
- $32.4M
- Introduction
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- MiNK Therapeutics
- Target Recruit Count
- 34
- Registration Number
- NCT05108623
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Norton Cancer Health, Louisville, Kentucky, United States
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- MiNK Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT04754100
- Locations
- 🇺🇸
Norton Cancer Institute - St. Matthews - Medical Oncology/Hematology Candida, Louisville, Kentucky, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- MiNK Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04582201
- Locations
- 🇺🇸
Saint John's Cancer Institute, Santa Monica, California, United States
🇺🇸Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States
🇺🇸Weill Cornell Medicine New York Presbyterian, New York, New York, United States
News
MiNK Therapeutics Achieves Complete Cancer Remission with Off-the-Shelf iNKT Cell Therapy
MiNK Therapeutics reported a complete and lasting remission in a patient with advanced testicular cancer using their experimental iNKT cell therapy agenT-797, published in Nature's Oncogene.
MiNK Therapeutics Reports Complete Remission in Metastatic Testicular Cancer Patient Using Allogeneic iNKT Cell Therapy
MiNK Therapeutics published a landmark case in Nature's Oncogene showing complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer following treatment with agenT-797, their allogeneic iNKT cell therapy.
MiNK Therapeutics Secures NIAID Grant to Develop iNKT Cell Therapy for Graft-Versus-Host Disease Prevention
MiNK Therapeutics has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance its allogeneic iNKT cell therapy platform for preventing graft-versus-host disease following stem cell transplantation.
LIfT BioSciences Appoints Dr. Mark Exley as CSO to Advance Novel Neutrophil Therapy into Clinical Trials
Dr. Mark Exley, a translational immunologist with 30 years of R&D experience, joins LIfT BioSciences as Chief Scientific Officer effective April 7, 2025.
Agenus to Present New Data on BOT/BAL Combination Therapy at AACR IO Meeting
Agenus will showcase interim data from a Phase 2 study combining BOT/BAL with iNKT cell therapy AgenT-797 in refractory gastric cancer patients at the AACR IO Annual Meeting.
MiNK Therapeutics' Allo-iNKT Cell Therapy Shows Promise in Refractory Gastric Cancer
MiNK Therapeutics' agenT-797, combined with botensilimab and balstilimab, demonstrates robust immune activation in refractory gastroesophageal cancer.